<DOC>
	<DOCNO>NCT01459432</DOCNO>
	<brief_summary>The main purpose study evaluate duration immunity booster dose MenC-CRM vaccine give adolescent 13 15 year age . Does seroprotection persist beyond teenage year early twenty ? This age group likely carry organism transmit member population . If booster dose MenC vaccine give adolescent produce protective level antibody persist early adulthood , would strengthen case booster add UK routine immunisation schedule , reduce risk resurgence disease future .</brief_summary>
	<brief_title>Understanding Immunity Persistence After Adolescent MenC Vaccination</brief_title>
	<detailed_description />
	<criteria>Participants complete clinical study M14P2E1 Participant willing participate would expect comply requirement protocol Participants give informed consent participation study History invasive meningococcal C disease ( case invasive meningococcal disease serotype unknown ) Confirmed suspect immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection Severe blood clotting disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>